Scotia Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,316
| Closed | -$1.02M | – | 968 |
|
|
2025
Q4 | $1.02M | Buy |
1,316
+183
| +16% | +$124K | ﹤0.01% | 563 |
|
|
2025
Q3 | $637K | Sell |
1,133
-3
| -0.3% | -$1.7K | ﹤0.01% | 631 |
|
|
2025
Q2 | $596K | Buy |
1,136
+6
| +0.5% | +$3.35K | ﹤0.01% | 603 |
|
|
2025
Q1 | $717K | Buy |
+1,130
| New | +$777K | ﹤0.01% | 562 |
|
|
2024
Q4 | – | Sell |
-1,077
| Closed | -$1.13M | – | 907 |
|
|
2024
Q3 | $1.13M | Buy |
1,077
+630
| +141% | +$701K | 0.01% | 493 |
|
|
2024
Q2 | $470K | Buy |
447
+14
| +3% | +$13.6K | ﹤0.01% | 613 |
|
|
2024
Q1 | $417K | Buy |
433
+22
| +5% | +$20.9K | ﹤0.01% | 628 |
|
|
2023
Q4 | $361K | Buy |
411
+117
| +40% | +$96.3K | ﹤0.01% | 628 |
|
|
2023
Q3 | $242K | Buy |
+294
| New | +$231K | ﹤0.01% | 683 |
|
|
2023
Q1 | – | Sell |
-383
| Closed | -$276K | – | 816 |
|
|
2022
Q4 | $276K | Sell |
383
-2
| -0.5% | -$1.48K | ﹤0.01% | 655 |
|
|
2022
Q3 | $265K | Sell |
385
-38
| -9% | -$23.9K | ﹤0.01% | 653 |
|
|
2022
Q2 | $250K | Buy |
423
+84
| +25% | +$54.6K | ﹤0.01% | 690 |
|
|
2022
Q1 | $237K | Sell |
339
-3,997
| -92% | -$2.53M | ﹤0.01% | 778 |
|
|
2021
Q4 | $2.74M | Buy |
4,336
+78
| +2% | +$48K | 0.02% | 355 |
|
|
2021
Q3 | $2.58M | Sell |
4,258
-3,175
| -43% | -$1.97M | 0.02% | 352 |
|
|
2021
Q2 | $4.15M | Sell |
7,433
-2,563
| -26% | -$1.3M | 0.03% | 273 |
|
|
2021
Q1 | $4.73M | Buy |
9,996
+42
| +0.4% | +$20.4K | 0.04% | 240 |
|
|
2020
Q4 | $4.81M | Buy |
9,954
+1,174
| +13% | +$634K | 0.04% | 216 |
|
|
2020
Q3 | $4.92M | Buy |
8,780
+924
| +12% | +$560K | 0.05% | 188 |
|
|
2020
Q2 | $4.9M | Buy |
7,856
+1,419
| +22% | +$805K | 0.07% | 155 |
|
|
2020
Q1 | $3.14M | Buy |
6,437
+5,879
| +1,054% | +$2.43M | 0.04% | 197 |
|
|
2019
Q4 | $210K | Buy |
+558
| New | +$188K | ﹤0.01% | 690 |
|
|
2019
Q3 | – | Sell |
-961
| Closed | -$301K | – | 773 |
|
|
2019
Q2 | $301K | Sell |
961
-395
| -29% | -$132K | ﹤0.01% | 603 |
|
|
2019
Q1 | $557K | Buy |
1,356
+542
| +67% | +$223K | 0.01% | 482 |
|
|
2018
Q4 | $304K | Buy |
814
+57
| +8% | +$20.9K | ﹤0.01% | 545 |
|
|
2018
Q3 | $306K | Sell |
757
-16
| -2% | -$6.09K | ﹤0.01% | 608 |
|
|
2018
Q2 | $262K | Buy |
773
+8
| +1% | +$2.5K | ﹤0.01% | 596 |
|
|
2018
Q1 | $263K | Buy |
+765
| New | +$266K | ﹤0.01% | 621 |
|
Other funds holding REGN
VCM
N
Scotia Capital's REGN Position: Q1 2026 in Review
Scotia Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1,316 shares — an estimated $1.02M sold.
Scotia Capital first reported a position in REGN in Q1 2018 and held it in 28 quarters. The position peaked at $4.92M in Q3 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Scotia Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Scotia Capital sold 1,316 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.02M.
- Scotia Capital first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 28 quarters.
- Scotia Capital's Regeneron Pharmaceuticals position peaked at $4.92M in Q3 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.